DaVita Inc stock (US23804L1035): Q1 2026 revenue tops estimates while valuation stays in focus

DaVita Inc shares on the NYSE remain in focus after the U.S. dialysis provider reported higher Q1 2026 revenue that beat analyst expectations, putting the spotlight on margins and valuation metrics ahead of the next earnings update.

DaVita Inc shares on the New York Stock Exchange remain closely watched after the U.S.-based dialysis and kidney care company reported higher first-quarter 2026 revenue that came in above Wall Street expectations, keeping attention on profitability and valuation as investors assess the outlook for the rest of the year.

According to an earnings review published on 05/03/2026, DaVita generated Q1 2026 revenue of USD 3.42 billion, representing year-on-year growth of about 6% and coming in roughly 2.1% above the analyst consensus cited in that analysis, which highlighted the quarter as a strong showing versus outpatient and specialty care peers.StockStory as of 05/03/2026

DaVita is headquartered in Denver in the United States and its primary listing is on the NYSE under the ticker DVA, which anchors the stock firmly in the U.S. healthcare universe for investors tracking domestic policy, reimbursement conditions, and broader movements in the S&P 500 health care space.

Market data providers estimate DaVita's equity market capitalization at about USD 12.36 billion as of 06/05/2026, implying a roughly 12.3% increase over the prior year and underscoring how steady share-price appreciation and buybacks have shaped the company’s equity value over the last twelve months.StockAnalysis as of 06/05/2026

For investors accessing the name from Germany, DaVita is also available via German trading venues such as Tradegate through secondary listings, allowing euro-based retail investors to trade the U.S. stock during extended European hours when liquidity permits.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: DVA
• Sector/industry: Healthcare - dialysis and outpatient kidney care
• Headquarters/country: Denver, United States
• Core markets: United States with selective international operations
• Key revenue drivers: Chronic kidney disease and end-stage renal disease treatment services, primarily in-center dialysis treatments reimbursed by public and private payers
• Home exchange/listing venue: NYSE (DVA)
• Trading currency: USD

DaVita Inc: core business model

DaVita Inc runs a global network of dialysis clinics and related kidney care services, focusing on patients with chronic kidney disease and end-stage renal disease under long-term treatment relationships with public and private insurers.

The company’s revenue is largely influenced by patient volumes, treatment frequency, payer mix, and reimbursement rates in the United States, complemented by a smaller contribution from international operations and value-based care arrangements where DaVita assumes shared financial responsibility for patient outcomes.

Valuation metrics and multiples for DaVita Inc

With Q1 2026 revenue of USD 3.42 billion reported on 05/03/2026 and a market capitalization around USD 12.36 billion as of 06/05/2026, DaVita continues to trade as a mid-cap U.S. healthcare provider that investors often compare on earnings and cash flow multiples with other outpatient and specialty care companies.StockStory as of 05/03/2026

While detailed forward-looking valuation ratios such as price-to-earnings and enterprise-value-to-EBITDA can fluctuate with both earnings delivery and share-price moves, the combination of mid-single-digit revenue growth in Q1 2026 and a rising market capitalization over the past year, as tracked by market data services on 06/05/2026, provides a reference point for investors monitoring how DaVita is priced against its cash generation and capital allocation plans.StockAnalysis as of 06/05/2026

Conclusion

DaVita Inc remains a notable U.S. healthcare stock after reporting Q1 2026 revenue of USD 3.42 billion on 05/03/2026, an outcome that exceeded the cited analyst consensus and underscored steady growth in its dialysis operations.

Against the backdrop of an estimated USD 12.36 billion market capitalization as of 06/05/2026, valuation discussions on DaVita continue to revolve around how its earnings trajectory, reimbursement landscape, and capital allocation choices will shape key multiples relative to other outpatient and specialty care providers on the NYSE.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.